We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+28.03%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$955M
AUM Growth
+$52.9M
Cap. Flow
-$132M
Cap. Flow %
-13.83%
Top 10 Hldgs %
81%
Holding
26
New
2
Increased
5
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$35.5M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$19.7M
3
COGT icon
Cogent Biosciences
COGT
+$16.4M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$10.8M
5
TYRA icon
Tyra Biosciences
TYRA
+$2.87M

Top Sells

Rank Stock Value
1
VERA icon
Vera Therapeutics
VERA
+$75.7M
2
IMGN
Immunogen Inc
IMGN
+$42.2M
3
MOR
MorphoSys AG American Depositary Shares
MOR
+$41.9M
4
NTRA icon
Natera
NTRA
+$30.1M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$23.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$183M 19.14%
2,000,000
-400,000
-17% -$30.1M
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.84B
$135M 14.1%
5,660,000
– –
CLDX icon
3
Celldex Therapeutics
CLDX
$2.77B
$122M 12.74%
2,900,000
-105,904
-4% -$4.35M
VERA icon
4
Vera Therapeutics
VERA
$2.54B
$65.8M 6.89%
1,526,787
-2,123,552
-58% -$75.7M
COGT icon
5
Cogent Biosciences
COGT
$6.79B
$57.1M 5.98%
8,500,000
+2,645,234
+45% +$16.4M
DVAX
6
DELISTED
Dynavax Technologies
DVAX
$52.6M 5.51%
4,239,780
+2,725,397
+180% +$35.5M
PCVX icon
7
Vaxcyte
PCVX
$7.89B
$50.9M 5.33%
745,000
-257,407
-26% -$17.8M
VRTX icon
8
PUT
Vertex Pharmaceuticals
VRTX
$121B
$41.8M 4.37%
+100,000
New +$42.3M
LQDA icon
9
Liquidia Corp
LQDA
$7.67B
$33.2M 3.47%
2,248,324
-450,000
-17% -$6.26M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.37B
$33.2M 3.47%
6,527,491
+1,927,491
+42% +$10.8M
PTGX icon
11
Protagonist Therapeutics
PTGX
$8.75B
$33.1M 3.46%
1,144,242
-860,633
-43% -$23.4M
TSVT
12
DELISTED
2seventy bio
TSVT
$31.9M 3.33%
5,953,825
– –
WVE icon
13
Wave Life Sciences
WVE
$1.12B
$24.3M 2.54%
3,932,082
– –
TVTX icon
14
Travere Therapeutics
TVTX
$5.33B
$15.4M 1.61%
2,000,000
– –
CORT icon
15
PUT
Corcept Therapeutics
CORT
$10.2B
$14.8M 1.54%
585,900
– –
IRWD icon
16
Ironwood Pharmaceuticals
IRWD
$611M
$14.2M 1.48%
+1,625,000
New +$19.7M
STRO icon
17
Sutro Biopharma
STRO
$379M
$11.3M 1.18%
200,173
– –
AMRN
18
Amarin Corp
AMRN
$284M
$10.7M 1.12%
601,148
– –
TYRA icon
19
Tyra Biosciences
TYRA
$1.82B
$8.45M 0.88%
515,190
+175,000
+51% +$2.87M
BNR
20
Burning Rock Biotech
BNR
$94.4M
$7.02M 0.73%
964,091
+94,648
+11% +$790K
CRBU icon
21
Caribou Biosciences
CRBU
$156M
$5.49M 0.57%
1,068,527
– –
SLRN
22
DELISTED
ACELYRIN
SLRN
$2.68M 0.28%
396,379
-803,621
-67% -$6.1M
VRDN icon
23
Viridian Therapeutics
VRDN
$2.13B
$2.34M 0.25%
133,877
-474,038
-78% -$9.19M
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-442,704
Closed -$3.52M
MOR
25
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-4,234,685
Closed -$41.9M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Kynam Capital Management held 26 positions worth $955M, up 5.9% from $903M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Kynam Capital Management withdrew a net $132M in Q1 2024, closing 3 positions and reducing 8 holdings. Its most notable exit was Immunogen Inc, an estimated $42.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier.

Against the trend, Kynam Capital Management opened a new position in Ironwood Pharmaceuticals worth $14.2M.

  • Kynam Capital Management's largest Q1 2024 buy was Ironwood Pharmaceuticals: 1,625,000 shares worth $14.2M.
  • Kynam Capital Management added most to Dynavax Technologies in Q1 2024, an estimated $35.5M increase.
  • Kynam Capital Management's biggest Q1 2024 reduction was Vera Therapeutics, cutting an estimated $75.7M.
  • Kynam Capital Management fully exited Immunogen Inc in Q1 2024, selling an estimated $42.2M.
  • Kynam Capital Management's ten largest holdings make up 81% of its $955M portfolio in Q1 2024.
  • Kynam Capital Management opened 2 new positions and closed 3 in Q1 2024.
  • Kynam Capital Management's portfolio value rose 5.9% quarter-over-quarter to $955M.

Based on Kynam Capital Management's 13F filing for Q1 2024, filed 15 May 2024.